Herpes simplex virus type 1 DNA replication occurs in nuclear domains termed replication compartments, which are areas of viral single-stranded DNA-binding protein (UL29) localization (M. P. Quinlan, L. B. Chen, and D. M. Knipe, Cell 36:857-868, 1984). In the presence of herpesvirus-specific polymerase inhibitors, UL29 localizes to punctate nuclear foci called prereplicative sites. Using versions of the helicase-primase complex proteins containing short peptide epitopes which can be detected in an immunofluorescence assay, we have found that the helicase-primase complex localizes to prereplicative sites and replication compartments. To determine if prereplicative site formation is dependent upon these and other essential viral replication proteins, we have studied UL29 localization in cells infected with replication-defective viruses. Cells infected with viruses that fail to express one of the three helicase-primase subunits or the origin-binding protein show a diffuse nuclear staining for UL29. However, in the presence of polymerase inhibitors, mutant-infected cells contain UL29 in prereplicative sites. Replication-defective viruses containing subtle mutations in the helicase or origin-binding proteins behaved identically to their null mutant counterparts. In contrast, cells infected with viral mutants which fail to express the polymerase protein contain prereplicative sites in the absence and presence of polymerase inhibitors. We propose that active viral polymerase prevents the formation of prereplicative sites. Models of the requirement of essential viral replication proteins in the assembly of prereplicative sites are presented.on July 10, 2020 by guest http://jvi.asm.org/ Downloaded from FIG. 3. UL29 localization in cells infected with viral mutants that fail to express UL5, UL8, UL52, or UL9. Vero cells were infected with 20 PFU of virus per cell and processed as described in Materials and Methods. (A) Cells were stained with 3-83 and fluorescein isothiocyanate-conjugated goat anti-rabbit secondary antibody. Cells were infected with the following mutants: panels A, B, and C, hr80; D, E, and F, hr99; G, H, and I, hr114. Infected cells in panels B, E, and H were treated with PAA, and those in panels C, F, and I were treated with ACG. Marker bar, 15 m. (B) hr94-infected cell doubly stained with antibodies (␣) for UL29 and BrdU. Panels A and B show the same group of hr94-infected cells doubly stained, respectively, with 3-83 (fluorescein isothiocyanate-conjugated goat anti-mouse secondary antibody) and anti-BrdU (Texas red-conjugated goat anti-mouse secondary antibody). Marker bar, 15 m.